Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Prothena Biosciences Limited

F. Hoffmann-la Roche Ag

Georg Tiefenthaler

Erhard Kopetzki

Jens Fischer

Guy Georges

Wolfgang Von Der Saal

Stefan Dengl

Ulrike Reiff

Joerg Moelleken

Sebastian Fenn

Ekkehard Moessner

Frederick Arthur Brookfield

Edward Andrew Boyd

Tilman Schlothauer

Hubert Kettenberger

Jens Niewoehner

Stefan Klostermann

Manfred Kubbies

Thomas Von Hirschheydt

Josef Endl

Gregor Jordan

Dieter Heindl

Stefan Seeber

Robin McDaid Barbour

Ulrich Brinkmann

Olaf Mundigl

Stefan Scheiblich

Kin-Chun Thomas Luk

Matthias Koerner

Konrad Honold

Petra Rueger

Wagner Marcelo Zago

Lothar Kling

Nikolaos Dimoudis

Gerhard Niederfellner

Eike Hoffmann

Sabine Hoves

Gang Xu

Peter Michael Huelsmann

Meher Majety

Anton Jochner

Shu Feng

Jonathan Gridley

Valeria Runza

Oliver Ploettner

Raymond Lau

Francesca Ros

Martin Schaefer

Ursula Schwarz

Claudia Kirstenpfad

Runyi Adeline Lam

Michael Gertz

Wei Shiong Adrian Ho

Siok Wan Gan

Maria Viert

Timothy Woodcock

Jianping Cai

Alexander Bujotzek

Bernhard Goller

Manfred Schwaiger

Claudio Bordignon

Adrian Hugenmatter

Brigitte Kaluza

Esther Koenigsberger

Ruediger Rueger

Cuiying Shao

Achim Gaertner

Simone Dethloff

Dominique Ostler

Andreas Hinz

Mariel Beck

Hilke Sudergat

Oliver Tonn

Kate Dora Games-Thiel

Tarlochan S Niijar

Simone Hoege

The present invention relates to anti-HLA-G antibodies and methods of using the same.

Anti-HLA-G antibodies and methods of use thereof

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformedcells.

Rapid method for cloning and expression of cognate antibody variable gene segments

Anti-HLA-G antibodies and use thereof

Herein is reported a method for producing a bispecific antibody comprising the step of incubating

Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof

Herein is reported a method for producing an enzymatic conjugation product of three polypeptides comprising the simultaneous incubation of i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide comprising the amino acid sequence LPXTA (SEQ ID NO: 31, wherein X can be any amino acid residue), a third polypeptide that has two N-termini whereby the polypeptide has an oligo-glycine G(m=2 (SEQ ID NO: 22), or 3 (SEQ ID NO: 23), or 4 (SEQ ID NO: 24), or 5 (SEQ ID NO: 25)) amino acid sequence at its first N-terminus and an oligo-alanine A(m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its second N-terminus, a fourth polypeptide with sortase activity whereby the polypeptide is derived fromsortase A, and a fifth polypeptide with sortase activity whereby the polypeptide is derived fromsortase A and the recovering of the conjugate from the reaction mixture.

Enzymatic one-pot reaction for double polypeptide conjugation in a single step

The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.

Covalently linked helicar-anti-helicar antibody conjugates and uses thereof

Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Monovalent blood brain barrier shuttle modules

Herein is reported a method for producing a polypeptide comprising at least two polypeptide domains comprising the step of cultivating a cell comprising (a) a nucleic acid encoding a solublesortase A with a C-terminal endoplasmic reticulum retention signal, (b) a nucleic acid encoding a first polypeptide domain comprising at its C-terminus a sortase motif followed by an endoplasmic reticulum retention signal, and (c) a nucleic acid encoding a second polypeptide domain comprising at its N-terminus at least a diglycine, whereby the cell secretes the sortase A conjugate of the first polypeptide domain and the second polypeptide domain, thereby producing a polypeptide comprising at least two polypeptide domains.

Method for the production and selection of molecules comprising at least two different entities and uses thereof

The current invention describes a nucleic acid comprising in a 5' to 3&#x2032; direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5&#x2032; splice donor site and terminated by a 3&#x2032; splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.

Polypeptide producing cells

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Pyridylsulfonamide derivatives

Growing community of inventors

Sindelsdorf, Germany

Georg Tiefenthaler